SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets

Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However,...

Full description

Bibliographic Details
Main Authors: Sandra N. Freiberger, Muriel Brada, Christine Fritz, Sylvia Höller, Alexander Vogetseder, Milo Horcic, Michel Bihl, Michal Michal, Martin Lanzer, Martin Wartenberg, Urs Borner, Peter K. Bode, Martina A. Broglie, Tamara Rordorf, Grégoire B. Morand, Niels J. Rupp
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
FNA
Online Access:http://www.sciencedirect.com/science/article/pii/S147655862100018X
id doaj-07d220f8e060469d809549e7e9a329cb
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Sandra N. Freiberger
Muriel Brada
Christine Fritz
Sylvia Höller
Alexander Vogetseder
Milo Horcic
Michel Bihl
Michal Michal
Martin Lanzer
Martin Wartenberg
Urs Borner
Peter K. Bode
Martina A. Broglie
Tamara Rordorf
Grégoire B. Morand
Niels J. Rupp
spellingShingle Sandra N. Freiberger
Muriel Brada
Christine Fritz
Sylvia Höller
Alexander Vogetseder
Milo Horcic
Michel Bihl
Michal Michal
Martin Lanzer
Martin Wartenberg
Urs Borner
Peter K. Bode
Martina A. Broglie
Tamara Rordorf
Grégoire B. Morand
Niels J. Rupp
SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
Neoplasia: An International Journal for Oncology Research
Salivary gland neoplasm
Biopsy
FNA
Molecular
Comprehensive
Testing
author_facet Sandra N. Freiberger
Muriel Brada
Christine Fritz
Sylvia Höller
Alexander Vogetseder
Milo Horcic
Michel Bihl
Michal Michal
Martin Lanzer
Martin Wartenberg
Urs Borner
Peter K. Bode
Martina A. Broglie
Tamara Rordorf
Grégoire B. Morand
Niels J. Rupp
author_sort Sandra N. Freiberger
title SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
title_short SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
title_full SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
title_fullStr SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
title_full_unstemmed SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
title_sort salvglanddx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
publisher Elsevier
series Neoplasia: An International Journal for Oncology Research
issn 1476-5586
publishDate 2021-05-01
description Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the “SalvGlandDx” panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.
topic Salivary gland neoplasm
Biopsy
FNA
Molecular
Comprehensive
Testing
url http://www.sciencedirect.com/science/article/pii/S147655862100018X
work_keys_str_mv AT sandranfreiberger salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT murielbrada salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT christinefritz salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT sylviaholler salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT alexandervogetseder salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT milohorcic salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT michelbihl salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT michalmichal salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT martinlanzer salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT martinwartenberg salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT ursborner salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT peterkbode salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT martinaabroglie salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT tamararordorf salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT gregoirebmorand salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
AT nielsjrupp salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets
_version_ 1721453449999024128
spelling doaj-07d220f8e060469d809549e7e9a329cb2021-05-10T07:02:45ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55862021-05-01235473487SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targetsSandra N. Freiberger0Muriel Brada1Christine Fritz2Sylvia Höller3Alexander Vogetseder4Milo Horcic5Michel Bihl6Michal Michal7Martin Lanzer8Martin Wartenberg9Urs Borner10Peter K. Bode11Martina A. Broglie12Tamara Rordorf13Grégoire B. Morand14Niels J. Rupp15Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology, Cantonal Hospital of Lucerne, Lucerne, SwitzerlandInstitute for Histological and Cytological Diagnostics AG, Aarau, SwitzerlandDepartment of Pathology and Medical Genetics, University Hospital Basel, Basel, SwitzerlandSikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Bioptical Laboratory, Pilsen, Czech RepublicDepartment of Oral and Maxillofacial Surgery, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandInstitute of Pathology, University of Bern, Bern, SwitzerlandDepartment of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital and University of Bern, Bern, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Medical Oncology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland; Department of Otolaryngology-Head and Neck Surgery, Sir Mortimer B. Davis- Jewish General Hospital, McGill University, Montreal, Quebec, Canada; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland; Corresponding author: Niels J. Rupp, MD, Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland, Tel. +41 44 255 50 91, Fax. +41 44 255 44 40Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the “SalvGlandDx” panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.http://www.sciencedirect.com/science/article/pii/S147655862100018XSalivary gland neoplasmBiopsyFNAMolecularComprehensiveTesting